Professor Michael Mahan's research concerns the molecular mechanisms of bacterial pathogenesis, and immune responses to infection and microbial sepsis. He received his B.S. degree in Biochemistry and M.S. degree in Genetics from the University of California, Davis; and a Ph.D. in Genetics from the University of Utah. He was a NIH post-doctoral fellow at Harvard Medical School where he began his work on the molecular mechanisms of underlying Salmonella pathogenesis. Dr. Mahan joined the UCSB faculty in 1993 and was co-founder and Director of Remedyne Corporation, a biotech company in Santa Barbara, California.
The Mahan lab investigates the molecular mechanisms underlying microbial pathogenesis and the associated innate and adaptive immune responses that increase disease and compromise host immunity. The applied goal is to translate this research into effective therapeutic strategies for the treatment of multidrug-resistant pathogens and microbial sepsis.